康躍科技(300391.SZ)擬定增募資不超1.4億元 用於總部運營中心及信息化建設等
格隆匯 3 月 9日丨康躍科技(300391.SZ)披露2021年度以簡易程序向特定對象發行股票預案,此次發行擬募集資金總額不超過(含)1.4億元,不超過人民幣三億元且不超過最近一年末淨資產百分之二十;在扣除相關發行費用後的募集資金淨額將全部用於以下項目:4000.00萬元用於總部運營中心及信息化建設;6000.00萬元用於醫藥研發中心建設;4000.00萬元用於補充流動資金。
此次發行股票數量不超過2000萬股(含此數),不超過此次發行前公司總股本的30%,最終發行股票數量由年度股東大會授權董事會根據具體情況與此次發行的主承銷商協商確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.